Search Results
Jun 22, 2026, 09:06 ET 蘆康沙妥珠單抗聯合奧希替尼一線治療EGFR突變NSCLC轉化研究成果刊發於《Cancer Cell》
果與臨床開發計劃，公司正在推進一項III期注冊研究（試驗編號：NCT06670196），將sac-TMT聯合奧希替尼與奧希替尼單藥一線治療局部晚期或轉移性EGFR突變非鱗狀NSCLC進行對比。該研究旨在評估sac-TMT（4 mg/kg，每兩周給藥一次）聯合奧希替尼相較於奧希替尼單藥在此適應症下的療效與安全性。該研究已在中國完成全部受試者入組，目前進入隨訪與數據成熟階段。除此之外，公司還在推進sac-TMT用於更早期EGFR突變NSCLC的臨床探索。一項II期臨床研究（試驗編號：NCT07329322）正在開展，評估sac-TMT聯合奧希替尼或sac-TMT單藥用於可切除EGFR突變NSCLC新輔助治療，進一步挖掘sac-TMT在圍手術期治療中的潛在價值。本次研究成果刊發於《Cancer
More news about: 科倫博泰
Jun 22, 2026, 09:00 ET Real Mushrooms® Debuts Real Mycelium™, a Pure Lion's Mane Mycelium Supplement Delivering a Clinically Verified Dose of Erinacine A
Mushrooms®, a global leader in organic mushroom extracts, today announced the launch of Real Mycelium™, delivering a clinically verified 5 milligram (mg) dose of Erinacine A per serving. Erinacine A is the key bioactive compound in Lion's Mane (Hericium erinaceus) mycelium, shown to support sharper
More news about: Real Mushrooms
Jun 22, 2026, 01:45 ET Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
treatment for locally advanced or metastatic EGFR-mutant non-squamous NSCLC. The study is designed to evaluate the efficacy and safety of sac-TMT (4 mg/kg, Q2W) plus osimertinib compared with osimertinib monotherapy in this indication. Patient enrollment in China has been completed, and the study is currently
More news about: Kelun-Biotech
![Best Infrared Saunas of 2026 [Expert Reviewed and Independently Verified]](https://mmx.prnewswire.com/media/MS1869793/2_person_rendering_-4-_-2.jpg?id=OA2726866&w=300)
Jun 21, 2026, 19:21 ET Best Infrared Saunas of 2026 [Expert Reviewed and Independently Verified]
170°F (GGR)EMF 0.5 mG (Vitatech) + VOC (VERT)
More news about: homesauna.com
Jun 19, 2026, 07:00 ET Joy Organics Enhances Popular CBD Salve with Double the CBD and Added Arnica
The updated formula now features 1,000mg of CBD per ounce and arnica for an elevated topical wellness experience. FORT COLLINS, Colo., June 19, 2026 /PRNewswire/ -- Joy Organics, a leader in premium hemp-derived
More news about: Joy Organics
Jun 19, 2026, 00:09 ET Trumpdrive Energy® Launches Jupiter Matcha Lychee. The First Cognitive Energy Drink to Fuse Matcha and Lychee in a Planetary-Inspired Formula
first cognitive energy drink to bring both together.The FormulaJupiter Matcha Lychee carries the Trumpdrive nootropic stack: 200mg plant-based caffeine, Cognizin® (Citicoline), Lion's Mane, Bacopa Monnieri, and L-Theanine, amplified by matcha's natural L-Theanine for a
More news about: Trumpdrive Energy
Jun 18, 2026, 11:00 ET Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
cancer who had received ≥ 1 line therapy (Phase lb), and who had no prior systemic chemotherapy (Phase ll). Patients received BFv 1.25mg/kg on days 1, 8 and Toripalimab at 240mg on day 1 of each 21-days cycle. The primary endpoints were safety and preliminary efficacy.As of March 19, 2026, a total of
More news about: Mabwell
Jun 18, 2026, 10:07 ET ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
toxicities and predominantly low-grade adverse events observed at all dose levels evaluated." What investors were not told was that a patient receiving 24 mg of ERAS-0015 had died. The patient experienced a Grade 3 treatment-related adverse event of pneumonitis that progressed to Grade 5. This fatal outcome
More news about: SueWallSt.com
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
after market hours on April 27, 2026, Erasca reported preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a "Grade 3 TRAE of pneumonitis" that "progressed
More news about: Pomerantz LLP
Jun 18, 2026, 06:55 ET IASO Bio Announces NDA Approval of Equecabtagene Autoleucel by the Singapore Health Sciences Authority (HSA) for the Treatment of Relapsed or Refractory Multiple Myeloma, Marking a Key Milestone in International Commercialization
lines of therapy. It is also being developed for use in earlier lines of r/r MM treatment and for autoimmune diseases, including myasthenia gravis (MG), multiple sclerosis (MS), and systemic lupus erythematosus (SLE)/lupus nephritis (LN). Beyond eque-cel, we are developing nine additional therapeutic
More news about: IASO Bio
Jun 18, 2026, 06:45 ET TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026
across all 29 participants was 32.1%, with ORRs of 33.3% in the 2.4 mg/kg cohort and 31.3% in the 3.0mg/kg.The disease control rate (DCR) across all participants was 92.9%, including 83.3% in the 2.4 mg/kg cohort and 100% in the 3.0mg/kg cohort.Clinical responses were observed in patients
More news about: TORL Biotherapeutics LLC
Jun 17, 2026, 11:56 ET Lupin Launches Azilsartan Medoxomil Tablets in the United States
Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Azilsartan Medoxomil Tablets, 40mg and 80mg in the United States following the approval from the U.S. FDA for its Abbreviated New Drug Application. The product is bioequivalent to Edarbi® of
More news about: Lupin Pharmaceuticals, Inc.
Jun 17, 2026, 10:28 ET GORGIE LAUNCHES NEW ROCKET POP PROTEIN FLAVOR, BRINGING THE ULTIMATE SUMMER SIP TO THE MODERN ENERGY SPACE
craveability, GORGIE's Rocket Pop Protein flavor delivers an energizing boost without sacrificing ingredient quality, taste, or aesthetic. Each can contains 150mg of green tea caffeine alongside functional wellness ingredients including Biotin, B Vitamins, and L-Theanine for smooth, sustained energy without the
More news about: GORGIE
Jun 17, 2026, 09:00 ET New Proof-of-Concept Study Explores Acute Cognitive Benefits of Cognizin®
changes in cognitive function and neuroelectric activity could be observed following just a single dose.The study assessed the effects of a 500 mg dose of Cognizin versus placebo in healthy male adults, measuring outcomes across electroencephalogram (EEG) brain wave analysis, validated cognitive
More news about: Kyowa Hakko U.S.A
Jun 17, 2026, 08:42 ET She Founded One of the Only Women-Led Brands in Hemp Cigarettes. Now, as Menthol Leaves the Shelves, Full Moons Club Opens Pre-Orders on Its First Cooled Blend.
as defined by the 2018 Farm Bill (no more than 0.3 percent delta-9 THC on a dry-weight basis), and Full Moons additionally holds each serving below 0.4mg of delta-9 THC."We make smokes for adults who already smoke and are not trying to quit," Brooks said. "We are not a wellness company and we are
More news about: Full Moons Club
Jun 17, 2026, 08:01 ET Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026
pharmacokinetics and target occupancy, a dose of 1,750 mg was selected as the recommended dose for expansion.Preliminary efficacy analysis focused on patients receiving active dose levels of NTX1088 (1200 and 1750 mg) in combination with pembrolizumab (200 mg). Among 41 evaluable patients, confirmed partial
More news about: Nectin Therapeutics, LTD.
Jun 17, 2026, 08:00 ET INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit
after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015
More news about: Robbins Geller Rudman & Dowd LLP
Jun 17, 2026, 06:28 ET Phase 1 MRX1 Study Delivers Strong Headline Data
Two dose levels were tested, 2.5 and 7.5 mg/kg of body weight. The effect of food was also assessed for lower dose level (2.5 mg/kg). A total of 20 participants received at least one dose of MRX1, with 10 participants 2.5 mg/kg twice daily and 10 receiving 7.5 mg/kg twice daily. After a 14-day wash-out
More news about: Ananda Pharma Limited
Jun 17, 2026, 06:15 ET Brilliance Without Boundaries: Epson Unveils New 30,000-Lumen4K Projector Built for World Class Immersive Environments
source for up to 20,000 hours. Approximate time until brightness decreases 50% from first usage. Measured by acceleration test assuming use of 0.04 - 0.20 mg/m3 of particulate matter. Time varies depending on usage conditions and environment. Replacement of parts other than the light source may be required
More news about: Epson America, Inc.
Jun 16, 2026, 16:05 ET Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
to Xyrem. Xywav has 131 mg of sodium at the maximum recommended nightly dose whereas other high sodium oxybates have 1640 mg at the equivalent dose. Xywav is comprised of a unique composition of cations resulting in 92% less sodium, or a reduction of approximately 1,000 to 1,500 mg/night at the recommended
More news about: Jazz Pharmaceuticals plc
Jun 16, 2026, 13:00 ET Proposta inédita busca viabilizar Wegovy® no SUS para pacientes com obesidade e alto risco cardiovascular
um estudo multicêntrico, randomizado, duplo-cego, controlado por placebo e dirigido por eventos, desenhado para avaliar a eficácia da semaglutida 2,4 mg em comparação ao placebo como um complemento ao tratamento padrão cardiovascular para reduzir o risco de eventos cardiovasculares adversos maiores em
More news about: Novo Nordisk
Jun 16, 2026, 12:36 ET Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studiesNew microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed
More news about: Optimi Health Corp
Jun 16, 2026, 10:00 ET Silicon Labs Advances Large-Scale Matter Deployments with 200-Node Matter-over-Thread Validation Network
inventory management and enabling a smoother transition between ecosystems. Silicon Labs supports CMP across its latest wireless platforms, including MG26 and Series 3 devices, helping developers build interoperable products that span multiple wireless ecosystems.The complete Matter Large Network
More news about: Silicon Labs
Jun 16, 2026, 08:48 ET GEM Launches GEM Daily Bite Product Featuring Earthlight® Whole Food Vitamin D Nationwide at Sprouts Farmers Markets, Bringing Whole Food Nutrition to the Vitamin Aisle
formulation by a range of nutrient-dense food and functional ingredients including 187.5 mg of beta glucans (whole algae fermented beta glucan), 2 billion CFU probiotics (Bacillus coagulans MTCC 5856), 250 mg of curcumin (turmeric extract), 52 mcg of vitamin K2 (chickpea fermentation), prebiotic
More news about: PLT Health Solutions
Jun 16, 2026, 08:35 ET Foundry Nation Expands Two Scoops THC Soda Line with New Classic Cola and Cream Soda Flavors
Nation, the Minnesota-based THC beverage brand known for reimagining nostalgic soda flavors, today announced the launch of two new additions to its 10mg Two Scoops THC Soda lineup: Classic Cola and Cream Soda. The new flavors build on the success of the Two Scoops collection, which combines familiar
More news about: Foundry Nation